Search

Displaying results 2021 - 2030 of 10000 in total
  1. Drug

    Nateglinide

    go.drugbank.com/drugs/DB00731
    Approved

    It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. … The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents.

  2. Drug

    Fenfluramine

    go.drugbank.com/drugs/DB00574
    ApprovedIllicitInvestigationalWithdrawn

    from the market in 1997. … Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor Agonists
  3. Drug

    Medroxyprogesterone acetate

    go.drugbank.com/drugs/DB00603
    ApprovedInvestigational

    [A14848] MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, … Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties.

    Categories: Sex Hormones and Modulators of the Genital SystemProducts: ACETATO DE MEDROXIPROGESTERONA SUSPENSION INYECTABLE 150MG
  4. Drug

    Cetyl alcohol

    go.drugbank.com/drugs/DB09494
    Approved

    Cetyl alcohol is reported to be a mild skin or eye irritant. … According to the FDA Code of Federal Regulations, cetyl alcohol is a safe synthetic fatty acid in food and in the synthesis of food components under the condition that it contain not less than 98 percent

  5. Drug

    Felbamate

    go.drugbank.com/drugs/DB00949
    Approved

    Alternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites. … Felbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization).

    Categories: NMDA Receptor Antagonists
  6. Drug

    Astemizole

    go.drugbank.com/drugs/DB00637
    ApprovedWithdrawn

    It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. … Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms.

  7. Drug

    Doxorubicin

    go.drugbank.com/drugs/DB00997
    ApprovedInvestigational

    [A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin … [A257709] Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and

  8. Drug

    Dofetilide

    go.drugbank.com/drugs/DB00204
    ApprovedInvestigational

    Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation … and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter.

  9. Drug

    Triamterene

    go.drugbank.com/drugs/DB00384
    Approved

    It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. … [L6163] Triamterene was approved by the Food and Drug Administration in the U.S. in 1964.

    Mixtures: TRIAMETERENO E HIDROCLOROTIAZIDA CAPSULAS
  10. Drug

    Lactulose

    go.drugbank.com/drugs/DB00581
    ApprovedInvestigational

    [L6202] Especially considering the use of lactulose as a laxative is typically only considered after lifestyle and dietary modifications fail and the fact that lactulose therapy cannot be ethically … withheld from patients diagnosed with PSE in a placebo study, the substance may just be one of many options available for treating constipation and its efficacy in managing PSE may never be formally confirmed

    Products: FLOROLAC 670MG/ML LOES Z E